-Down to Earth US actions jeopardise India's pro-poor patent laws that promote generic drugs production, says online global petition More than 75,000 people have requested Prime Minister Narendra Modi not to succumb to US pressure on Intellectual Property Rights (IP). With trade and intellectual property rights featuring prominently in the agenda of US president Barak Obama's India visit, civil society groups have expressed concern that talks on these issues are designed to make...
More »SEARCH RESULT
MDG-led healthcare policy not comprehensive, says report -Jyotsna Singh
-Down to Earth In a Union budget wish list, civil society organisations call for course correction in policy and improving access to healthcare in India The government's focus on improving health indicators stated in the Millennium Development Goals (MDGs) has worked against the aims of universal health coverage, said experts at the National Convention on Union Budget 2015-16 held in Delhi on January 8 and 9. They recommended that the focus must...
More »Improving Healthcare Services at Reduced Prices -Meeta Rajivlochan
-Economic and Political Weekly The key to improving the quality of healthcare services in India and reducing costs at the same time can be found by enacting legislation which lays down minimum standards of patient care. In the absence of such standards and the reluctance of health insurance companies to standardise either price or quality, healthcare services continue to be expensive and of doubtful quality. Developing standards of patient care by...
More »Delhi High Court dismisses plea for supply of Generic medicines -Mohammed Iqbal
-The Hindu New Delhi: While observing that the Court could not encroach into policy matters of the government, the Delhi High Court has dismissed a public interest writ petition seeking directions to the Centre to make available Generic medicines and medical treatment to the public at large at a reasonable cost. A Division Bench comprising Chief Justice G. Rohini and Justice R.S. Endlaw had earlier this week said that the Centre and...
More »Generic drug makers get a boost from SC ruling -Ramnath Subbu
-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the...
More »